ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      83.015
      -0.13%
      Bitcoin
      64,097.98
      0.15%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Syros Pharmaceuticals Inc (SYRS)

      7. Syros Pharmaceuticals Inc (SYRS) News

      SYRS

      Syros Pharmaceuticals (SYRS)

      Syros Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:SYRS
      DateTimeSourceHeadlineSymbolCompany
      04/09/20247:00AMBusiness WireSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionNASDAQ:SYRSSyros Pharmaceuticals Inc
      04/02/20244:30PMBusiness WireSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SYRSSyros Pharmaceuticals Inc
      03/27/20247:30AMBusiness WireSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
      03/27/20246:57AMIH Market NewsU.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early TradingNASDAQ:SYRSSyros Pharmaceuticals Inc
      03/25/20247:00AMBusiness WireSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialNASDAQ:SYRSSyros Pharmaceuticals Inc
      03/20/20247:00AMBusiness WireSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
      02/27/20247:00AMBusiness WireSyros to Participate in TD Cowen 44th Annual Health Care ConferenceNASDAQ:SYRSSyros Pharmaceuticals Inc
      02/14/20248:56PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SYRSSyros Pharmaceuticals Inc
      02/13/20248:22PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
      02/13/20247:02PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
      02/13/20246:59PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
      01/08/20247:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
      01/08/20247:00AMBusiness WireSyros Highlights Anticipated 2024 Milestones to Deliver on the Value of TamibaroteneNASDAQ:SYRSSyros Pharmaceuticals Inc
      01/02/20244:15PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/26/20235:19PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
      12/19/20234:59PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/19/20234:53PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SYRSSyros Pharmaceuticals Inc
      12/19/20237:27AMBusiness WireSyros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/14/20234:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/12/20234:12PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/08/20234:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/06/20234:00PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/06/20237:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/06/20237:00AMBusiness WireSyros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and AzacitidineNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/05/20235:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
      11/21/20237:30AMBusiness WireSyros to Participate in Upcoming Investor ConferencesNASDAQ:SYRSSyros Pharmaceuticals Inc
      11/14/20237:30AMBusiness WireSyros Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
      11/14/20236:47AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRSSyros Pharmaceuticals Inc
      11/07/20237:30AMBusiness WireSyros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023NASDAQ:SYRSSyros Pharmaceuticals Inc
      11/02/20234:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:SYRS